Norwegian Association for Cardiothoracic Surgery

Slides:

Advertisements

Similar presentations

Thoracic surgery in Norway 2010 Norwegian Association for Cardiothoracic Surgery Norwegian register for general thoracic surgery. Steinar Solberg, MD,

Advertisements

LUNG CANCER LUNG CANCER Lung Cancer  What Is Lung Cancer?  Lung Cancer is a disease caused by the rapid growth and division of cells that make up the.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.

Norwegian register for general thoracic surgery.

Norwegian register for general thoracic surgery.

Treatment of Stage I and II Non-small Cell Lung Cancer

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2009 Norwegian Association for Cardiothoracic Surgery Jan L.Svennevig, MD,PhD.

A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2005 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2006 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis Erik.

Krdžalic Goran, Mušanović Nermin, Kešetović Amar

Prognosis of younger patients in non-small cell lung cancer

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2007 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.

Cancer of the Head and Neck and HPV Infection

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Treatment of Stage I and II Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program Giulia Veronesi, MD, Massimo Bellomi, MD,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2004 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.

Liverpool Heart and Chest Hospital

Data from The Society of Thoracic Surgeons General Thoracic Surgery database: The surgical management of primary lung tumors Daniel J. Boffa, MD, Mark.

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis Erik.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Lymph Node Evaluation by Open or Video-Assisted Approaches in 11,500 Anatomic Lung Cancer Resections Daniel J. Boffa, MD, Andrzej S. Kosinski, PhD, Subroto.

Joshua E. Rosen, BASc, Michelle C

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Surgical Treatment of Metachronous Second Primary Lung Cancer

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Superior sulcus (Pancoast) tumor: experience with 105 patients

Surgical treatment of non-small cell lung cancer 1 cm or less in diameter Daniel L Miller, MD, Charles M Rowland, MS, Claude Deschamps, MD, Mark S Allen,

Treatment of Stage I and II Non-small Cell Lung Cancer

Robert James Cerfolio, MD, FACS, FCCP, Ayesha S

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Outcomes for Thoracoscopy Versus Thoracotomy Not Just Technique Dependent: A Study of 9,787 Patients Andrea Wolf, MD, MPH, Bian Liu, PhD, Emanuele Leoncini,

Narcissus, the beam and lung cancer: What is the message?

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Variation in Hospital Adoption Rates of Video-Assisted Thoracoscopic Lobectomy for Lung Cancer and the Effect on Outcomes Zaid M. Abdelsattar, MD, MS,

Video-Assisted Thoracoscopic Surgery is More Favorable Than Thoracotomy for Resection of Clinical Stage I Non-Small Cell Lung Cancer Bryan A. Whitson,

Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality Christopher M. Pezzi, MD, Katherine Mallin, PhD, Andres Samayoa.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Is surgery for multiple lung metastases reasonable

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

It’s All in the “Swerve of the Curve”

NAACCR/IACR Combined Annual Conference 2019

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Neal S Goldstein, MD The Annals of Thoracic Surgery

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Mark W. Hennon, MD, Elisabeth U

The Society of Thoracic Surgeons Composite Score for Rating Program Performance for Lobectomy for Lung Cancer Benjamin D. Kozower, MD, MPH, Sean M. O’Brien,

Time-related mortality for women after coronary artery bypass graft surgery: a population-based study Veena Guru, MD, Stephen E Fremes, MD, MSc, Jack.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Norwegian Association for Cardiothoracic Surgery Thoracic surgery in Norway 2016 Norwegian Association for Cardiothoracic Surgery Norwegian register for general thoracic surgery. Steinar Solberg, MD, PhD. Department of Thoracic and Cardiovascular Surgery Rikshospitalet, Norway steinar.solberg@rikshospitalet.no

Summary, 2016 The number of general thoracic operations is stable – some 1500 per year. All eight hospitals have reported their operations for 2016. For the first year the number of thoracosopies (699) is higher than the thoracotomies (698). The number of mediastinoscpies is very low – 22 procedures in 2016. Surgery for lung cancer is increasing. 693 operations were reported. Of these 39 % were performed by thoracoscopic technique. No hospital in Norway can offer robotic technique in lung cancer surgery. All curative modalities in lung cancer treatment are increasing and some 40 % of the patients are now offered curative surgery, stereotacic radiation or chemo- radiotherapy. Very low mortality, both 30 and 90 days after surgery for lung cancer! Continuously increasing survival after 1, 2 and 5 years in both men and women diagnosed with lung cancer. Norwegian Association for Cardiothoracic Surgery

Number of general thoracic operations reported Norwegian Association for Cardiothoracic Surgery

Number of operations per hospital per year Norwegian Association for Cardiothoracic Surgery

Accesses used Norwegian Association for Cardiothoracic Surgery

Underlying diagnoses Norwegian Association for Cardiothoracic Surgery

Organ operated upon Norwegian Association for Cardiothoracic Surgery

Selected operations performed Norwegian Association for Cardiothoracic Surgery

Number of operations for lung metastases performed annually Norwegian Association for Cardiothoracic Surgery

Operations for lung cancer Norwegian Association for Cardiothoracic Surgery

Number of operations for lung cancer per hospital per year Norwegian Association for Cardiothoracic Surgery

Prosedures performed in operations for lung cancer Norwegian Association for Cardiothoracic Surgery

The percentage of resections for lung cancer performed by From the Cancer Registry of Norway, 2016 The percentage of resections for lung cancer performed by thoracoscopy (VATS)

The number (columns) and percentage (line) of operations for lung cancer performed by VATS / thoracoscopic lobectomies Norwegian Association for Cardiothoracic Surgery

The percentage of patiens beeing females in surgery for lung cancer Norwegian Association for Cardiothoracic Surgery

Median (min – max) age for patients operated for lung cancer 2011 - 2015 2012 2013 2014 2015 2016 Females 66 (19-87) 67 (30-85) (8-85) 68 (36-86) 69 (19-84) Males (20-84) (37-85) (43-86) (31-89) (9-86) Norwegian Association for Cardiothoracic Surgery

The age distribution in 6852 patients operated for lung cancer 2003 - 2016 Norwegian Association for Cardiothoracic Surgery

The number (columns) and percentage (line) of patients operated for lung cancer beeing 80 years or older Norwegian Association for Cardiothoracic Surgery

Location of tumor in 6190 operations for lung cancer 2003-2016 1960 (32 %) 1620 (26 %) 375 (6 %) 1207 (19 %) 1028 (17 %) 3542 (57 %) 2648 (43 %)

The Cancer Registry of Norway Improved survival after 1, 2 and 5 years in the whole group of lung cancer patients. The Cancer Registry of Norway http://www.kreftregisteret.no/ Norwegian Association for Cardiothoracic Surgery

From the Cancer Registry of Norway, 2016 The stage distribution, based on pTNM for the patients operated for lung cancer

The percentage of the patients operated, with cN2 – known From the Cancer Registry of Norway, 2016 The percentage of the patients operated, with cN2 – known spread of cancer to one or more regional lymph node(s) before surgery.

The percentage of the patients From the Cancer Registry of Norway, 2016 The percentage of the patients diagnosed with lung cancer that has been operated.

The percentage of the patients From the Cancer Registry of Norway, 2016* The percentage of the patients diagnosed with lung cancer that has been treated with intention to cure – eg: Surgery: 21% Stereotactic radiation: 8 % Chemo-radiation: 8 % TOTAL: 37 % !! *The figures given are from 2015.

surgery for lung cancer From the Cancer Registry of Norway, 2016 30 days mortality after surgery for lung cancer

surgery for lung cancer From the Cancer Registry of Norway, 2016 90 days mortality after surgery for lung cancer

T A K K